Heart muscle contraction is regulated via the b-adrenergic response that leads to phosphorylation of Troponin I (TnI) at Ser22/23, which changes the Ca 2+ sensitivity of the cardiac myofilament. Mutations in thin filament proteins that cause dilated cardiomyopathy (DCM) and some mutations that cause hypertrophic cardiomyopathy (HCM) abolish the relationship between TnI phosphorylation and Ca 2+ sensitivity (uncoupling). Small molecule Ca 2+ sensitizers
Introduction
Hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM) are common inherited diseases. HCM is detected in 1 in 500 of the adult population, and the causative mutations are overwhelmingly in the proteins of the cardiac muscle contractile apparatus. 1, 2 At least 30% of cases of idiopathic DCM are of genetic origin, and DCM with no additional complications such as conduction disease is usually caused by mutations in the contractile apparatus. 3, 4 In many cases, the cardiomyopathies result from missense mutations in one of the proteins of the muscle thin filament (actin, tropomyosin, troponin I, C, or T). Investigations of the mechanisms that cause HCM and DCM have generally found that mutations in the muscle thin filament cause abnormalities in the Ca 2+ regulatory system of the muscle. 5 -7 HCM is closely associated with enhanced myofilament Ca 2+ sensitivity, although the process by which chronically high Ca 2+ sensitivity leads to the symptoms of HCM, hypertrophy, fibrosis, and arrhythmias, is uncertain. In DCM, the situation is more complex. It has been suggested that DCM-causing mutations are associated with a reduced Ca 2+ sensitivity, 8 but comprehensive surveys now show that DCM-causing mutations in thin filament proteins can increase or decrease Ca 2+ sensitivity. 5, 9 However, the DCM phenotype is always linked to the absence of modulation of Ca 2+ sensitivity by troponin I (TnI) phosphorylation (uncoupling), and this has been proposed to be causative of the DCM phenotype. 9, 10 In addition, the coupling between TnI phosphorylation and change of Ca 2+ sensitivity seems to be lost due to HCM mutations in thin filament proteins when studied by in vitro motility assay (IVMA) techniques and by myofibrilar assays, 11 -15 but in permeabilized muscle, this phenomenon is not observed. 16 Thus, in HCM, the relationship between TnI phosphorylation and Ca 2+ sensitivity is not clear.
Uncoupling appears to be closely associated with mutations in thin filament proteins that cause cardiomyopathies. The decrease in Ca 2+ sensitivity upon phosphorylation of TnI and the corresponding increase in the rate of Ca 2+ dissociation from troponin C (TnC) is a key component of the lusitropic response to b1-adrenergic stimulation in the heart. The uncoupling reported in DCM and HCM is likely to impact on cardiac reserve pathologically, and indeed, most studies of mouse models with cardiomyopathy mutations in thin filament proteins report a blunted response to adrenergic stimulation in vivo (reviewed in Ref. 17) .
A number of small molecules have been found that alter myofilament Ca 2+ sensitivity by binding to troponin and act as either Ca 2+ sensitizers or Ca 2+ desensitizers. The effect of these reagents on Ca 2+ sensitivity is well documented, but the effect of small molecules on the coupling between Ca 2+ sensitivity and TnI phosphorylation has not previously been considered. EMD57033 and Bepridil are well-established Ca 2+ sensitizers acting directly upon TnC. 18 -20 Epigallocatechin-3-gallate (EGCG), the principal polyphenol isolated from green tea, is reported to be a Ca 2+ desensitizer that also acts via a binding site on TnC. 21 -23 Troponin was isolated from 100 mg of human heart muscle using an anti-cardiac TnI mAb affinity column as described by Messer. 29 Troponin containing the TNNC1 G159D mutation was purified from explanted heart samples as previously described. 9, 30, 31 Recombinant TNNT2 K280N and TNNI3 K36Q was introduced into donor heart troponin by exchange as described. 29, 32 Wild-type a-tropomyosin (Tpm1.1) and the mutants E40K, E54K, and E180G were expressed in a baculovirus/Sf9 system with a protocol based on that of Akkari et al. 9, 33, 34 Native, E361G, and E99K mutant mouse cardiac actins were extracted from transgenic mouse hearts as described by Song et al. 35 
Manipulation and measurement of TnI phosphorylation level
Troponin isolated from human heart samples has a high level of phosphorylation, which was reduced by treatment with shrimp AP (Sigma P9088). Recombinant TnI was phosphorylated by treatment with protein kinase A (PKA) catalytic subunit (Sigma, P2645-400) as previously described.
9,32
To dephosphorylate mouse heart troponin, mice were treated with propranolol as described. 10 TnI phosphorylation levels in myofibrils and isolated troponin were measured by Phosphate affinity SDS -PAGE as described; 9, 36 results are shown in Supplementary material online, SC.
Quantitative IVMA
Thin filaments were reconstituted with 10 nM rabbit skeletal or mouse cardiac muscle a-actin (labelled with TRITC phalloidin), tropomyosin (40 -60 nM), and troponin (60 nM) to study Ca 2+ regulation of filament motility by the quantitative IVMA. 29, 37 Thin filament movement over a bed of immobilized rabbit fast skeletal muscle heavy meromyosin (100 mg/mL) was compared in paired motility chambers in which troponin varied by a single factor (mutation, phosphorylation state, or treatment with drug). Filament movement was recorded and analysed as previously described, 38 yielding two parameters, the fraction of filaments moving, and the speed of moving filaments.
Contraction of isolated myofibrils
Contraction and relaxation of isolated mouse myofibrils were initiated using a fast-solution change system and sensitive force transducer system recently described. 10 Further details are in Supplementary material online, SA.
Results

Relationship between phosphorylation and Ca 21 sensitivity
We measured the Ca 2+ dependence of thin filaments containing human heart troponin by the IVMA. The assay yields two parameters, fraction of filaments motile and sliding speed of the motile thin filaments. Both parameters are Ca 2+ dependent, and Ca 2+ activation curves were plotted ( Figure 1 Figure 1A ). We have investigated thin filaments incorporating six DCM-causing mutations that have been shown to abolish this relationship (uncouple) in previous studies 9 and three HCM mutations that uncouple in vitro Figure 2A and D) and slightly increased the maximum sliding speed of native human thin filaments as expected. The effect of EMD57033 on EC 50 for Ca 2+ activation of motility was biphasic with a maximum at 30 mM and an EC 50 in the range of 15 -20 mM ( Figure 2C ). Interestingly, we observed that 30 mM EMD57033 increased the Ca 2+ sensitivity of thin filaments containing phosphorylated troponin more than unphosphorylated TnI (mean ratio EC 50 P/EC 50 P + EMD57033 ¼ 3.07 + 0.71, P ¼ 0.0001, n ¼ 4 in phosphorylated compared with a mean ratio of EC 50 unP/EC 50 unP Table 1 , Figure 2A , see Supplementary material online, SB). Consequently, in the presence of EMD57033, Ca 2+ sensitivity of thin filaments was the same, independent of the level of phosphorylation (EC 50 P + EMD57033/EC 50 unP + EMD57033 ¼ 1.08 + 0.03, P ¼ 0.06, n ¼ 4). EMD57033 increased sliding speed slightly at saturating Ca 2+ concentration in phosphorylated thin filaments and in unphosphorylated thin filaments by 18.4 + 4.1% (P ¼ 0.02, n ¼ 4). n H was slightly decreased in phosphorylated but not in unphosphorylated thin filaments. EMD57033 also increased the Ca 2+ sensitivity of thin filaments containing the DCM-causing mutations, TPM1 E40K and E54K. In both these cases, Ca 2+ sensitivity was independent of troponin phosphorylation (uncoupled) due to the mutation (Table 1, Figure 2B ). A similar pattern of results was observed with Bepridil. The dose-response curve was cooperative with a calculated EC 50 of 52 mM ( Figure 2F ). At 100 mM, which is the saturated concentration, the increase in Ca 2+ sensitivity of phosphorylated donor thin filaments (measured by the mean ratio EC 50 P/EC 50 P + Bepridil) was 2.8 + 0.14-fold for fraction motile (P , 0.0001, n ¼ 6) and 3.09 + 0.59-fold for sliding speed (P ¼ 0.016, n ¼ 6), see Supplementary material online, SB.
Bepridil increased the Ca 2+ sensitivity of thin filaments and also uncoupled Ca 2+ sensitivity from TnI phosphorylation, as shown by the EC 50 ratios of phosphorylated to dephosphorylated troponin (EC 50 P/EC 50 unP ¼ 1.73 + 0.03, P , 0.0001; EC 50 P + Bepridil/EC 50 unP + Bepridil ¼ 1.03 + 0.01, P ¼ 0.04, n ¼ 6) ( Figure 2D , see Supplementary material online, SB). Bepridil increased sliding speed at saturating Ca 2+ concentrations significantly in phosphorylated thin filaments (14.8 + 3.2%, P ¼ 0.006, n ¼ 6) but did not have a significant effect in unphosphorylated thin filaments (7.2 + 4.6%, P ¼ 0.18, n ¼ 6); it had no significant effect on n H . Bepridil also reversibly increased the Ca 2+ sensitivity of both phosphorylated and unphosphorylated thin filaments containing the DCM-causing TPM1 E54K mutation, and these mutant thin filaments remained uncoupled ( Figure 3A , see Supplementary material online, SB).
EGCG restores coupling to HCM and DCM mutant thin filaments and myofibrils
EGCG also affected Ca 2+ sensitivity in thin filaments containing mutations associated with HCM or DCM in a phosphorylationdependent way. This was tested with five DCM-causing mutations and three HCM-causing mutations. EGCG decreased the Ca 2+ sensitivity of phosphorylated mutant thin filaments in a similar way to wild-type troponin (ratio EC 50 with/without EGCG was 1.36 -2.85). However, with unphosphorylated troponin, EGCG tended to have no effect or, in the case of the three tropomyosin mutations, increased Ca 2+ sensitivity ( Table 2) . As a result, the dependence of Ca 2+ sensitivity on TnI phosphorylation level was restored. For example, thin filaments containing the DCM-causing TPM1 mutation E54K were uncoupled with EC 50 of 0.106 + 0.013 mM for phosphorylated and 0.114 + 0.019 mM for unphosphorylated giving a ratio of 0.95 + 0.03 compared with a ratio of 2.24 + 0.10 for wild-type thin filaments ( Table 1 ). In the presence of 100 mM EGCG, the EC 50 was 0.23 + 0.03 mM for phosphorylated and 0.071 + 0.005 mM for unphosphorylated giving a ratio of 3.17 + 0.37 (P ¼ 0.004, n ¼ 5) (Table 1, Figure 3B) . A dose-response assay for recoupling yielded an EC 50 of 58.8 + 13.3 mM ( Figure 3D ). Similarly, EGCG was able to reversibly restore coupling of all the thin filament HCM and DCM-causing mutations in this study ( 
The effect of EGCG on contraction of myofibrils
We studied the effect of EGCG on mouse myofibril contractility in basally phosphorylated and dephosphorylated states, obtained EMD57033 and EGCG effects on cardiomyopathy mutations by treating mice with propranolol prior to sacrifice (Table 3, Figure 6 ). We found that 10 mM EGCG decreased Ca 2+ sensitivity of isometric force for both phosphorylated and unphosphorylated mouse myofibrils equally (EC 50 P/EC 50 P + EGCG ¼ 0.50 + 0.06, P , 0.001, n ¼ 9, EC 50 unP/EC 50 unP + EGCG ¼ 0.45 + 0.07, P , 0.00, n ¼ 5). Consequently, the effect of phosphorylation on Ca 2+ sensitivity in wild-type myofibrils was preserved in the presence of EGCG (EC 50 P + EGCG/EC 50 unP + EGCG ¼ 1.64 + 0.24, P , 0.001, n ¼ 5).
As previously shown, 10 in myofibrils from ACTC E361G DCM mice, the Ca 2+ sensitivity of force is uncoupled ( . Initially, motility is the same (see Figure 1) ; the addition of EGCG reduced motility of phosphorylated and increased motility of unphosphorylated thin filaments, indicating recoupling or the restoration of the phosphorylation-dependent Ca 2+ sensitivity difference (see Figure 3B ). Details as in Figure 2F . (5) Ratios: single value t-test compared with 1. ANOVA analysis of this data set is shown in Supplementary material online, SE. EC 50 values rounded to two significant figures. The number of experiments is given in brackets. *P , 0.05, **P , 0.01, for the presence and absence of EGCG using paired t-test. † P , 0.05, † † P , 0.01, unphosphorylated compared with phosphorylated using paired t-test.
EMD57033 and EGCG effects on cardiomyopathy mutations myofibrils ( Table 3 ). The duration of the initial, nearly isotonic, phase of relaxation, t LIN , in phosphorylated and unphosphorylated ACTC E361G myofibrils was restored to wild-type values ( Table 3) . EGCG decreased the rate of force development (k ACT ) but did not affect maximum force.
k ACT was decreased by EGCG in unphosphorylated wild-type myofibrils (decreased by 22.8%, P ¼ 0.059, n ¼ 15) as well as in phosphorylated and unphosphorylated ACTC E361G (decreased by 23%, P , 0.05, n ¼ 10 and by 21%, P , 0.001, respectively, n ¼ 11).
Discussion
In previous studies, it was found that mutations in proteins of the cardiac muscle thin filament that are associated with inherited cardiomyopathies (HCM and DCM) alter myofibrillar Ca 2+ sensitivity. They also cause the modulation of myofilament Ca 2+ sensitivity to become independent of the PKA-dependent phosphorylation of TnI. We have named this phenomenon uncoupling. Moreover, this uncoupling effect may be sufficient to generate the disease phenotype of familial DCM. 9, 17 We have investigated whether small molecules might be able to mimic or reverse the molecular effects of mutations. The Ca 2+ sensitizers EMD57033 and Bepridil, known to bind to TnC, induce uncoupling in wild-type thin filaments, thus mimicking the effects of HCM mutations. The Ca 2+ desensitizer EGCG has an opposite effect. It preserves coupling in wild-type troponin and restores coupling to thin filaments with HCM-and DCM-causing mutations in TnI, TnC, TnT, tropomyosin, and actin, thus antagonizing the effect of the HCM or DCM mutation. These findings suggest the potential of EGCG for treating the symptoms of inherited cardiomyopathies.
Ca 21 sensitizers mimic the effects of HCM-causing mutations in thin filaments
Both EMD57033 and Bepridil increase Ca 2+ sensitivity of phosphorylated thin filaments by 2.8-and 2.9-fold, measured by quantitative Figure 5 and summarized in Table 2 . Figure 5 The re-coupling effect of EGCG. The ratio of EC 50 phosphorylated/EC 50 unphosphorylated (coupling constant) is plotted in the absence (blue) and presence (green, red, and purple) of 100 mM EGCG. Green, control troponin; red, DCM-causing mutants; purple, HCM-causing mutants, error bars are +SEM. All the mutant samples are uncoupled, but the coupling constant is restored to control levels by EGCG. Data from Table 2 .
IVMA, in common with previous measurements. 40, 41 However, it has not been shown before that they increase Ca 2+ sensitivity of unphosphorylated thin filaments considerably less than phosphorylated thin filaments. As a consequence, Ca 2+ sensitivity becomes independent of the TnI phosphorylation level (uncoupled).
The effect of Ca 2+ sensitizers is analogous to the effect of HCM-causing mutations in vitro ( Effects of the ACTC E361G mutation, phosphorylation, and EGCG on the mean EC 50 (+SEM) for myofibril isometric contraction. Significant differences, calculated by t-test, between phosphorylated and unphosphorylated myofibrils are indicated: **P , 0.01; ***P , 0.001. Data from Table 3 .
EMD57033 and EGCG effects on cardiomyopathy mutations
have subsequently been demonstrated by in vitro assays, 5, 17 as the TPM1 E180G mutation, shown in Figure 1B , demonstrates.
Mechanistic considerations of Ca 21 sensitizers
Since both EMD57033 and Bepridil appear to modulate Ca 2+ sensitivity with a minimal effect on the sliding speed in IVMA or maximum isometric force in muscle fibres, 10, 42 it is likely that they are acting on troponin rather than the cross-bridge cycling mechanism in our systems.
The Ca 2+ sensitivity of cardiac troponin is modulated by the unique N-terminal peptide of TnI (1 -30) tizer shifts the conformational equilibrium so far towards the N-terminal bound conformation that it cannot be significantly influenced by phosphorylation of the N-terminal peptide of TnI (see Supplementary material online, SD). However, the Ca 2+ -sensitizing property of these compounds does not necessarily involve the same molecular mechanism as uncoupling. The actions of small molecules that uncouple highlight the crucial role of the allosteric coupling between the TnI 1 -30 peptide and ligand-binding sites that could be remotely located. Likewise, it is notable that DCM-causing mutations that uncouple are distributed in all the proteins of the thin filament, also demonstrating long-range allosteric interactions. 9, 47 We have proposed that these mutations destabilize the unphosphorylated state of the 1-30 peptide. (Figures 2, 3 , and 6).
EGCG was also able to decrease the Ca 2+ sensitivity of phosphorylated thin filaments containing HCM-and DCM-causing mutations; however, it had different effects on phosphorylated and unphosphorylated thin filaments. With phosphorylated troponin, EGCG decreased Ca 2+ sensitivity similarly to wild-type troponin, but EGCG either had no effect or increased Ca 2+ sensitivity with unphosphorylated troponin ( Although uncoupling can be clearly demonstrated at the level of skinned muscle fibres or myocytes with thin filament mutations causing DCM, 35, 48, 49 this does not appear to be true for HCM-causing mutations, despite being indistinguishable at the single filament level. A nearnormal response of Ca 2+ sensitivity to TnI phosphorylation has been reported for TNNC1 L29Q and TPM1 E180G in transgenic mice 50, 51 and TNNI3 R145W and TNNT2 K280N in human heart myectomy samples. 16 Despite this, both DCM-and HCM-linked mutations in transgenic mice models are associated with an impaired response to b1-adrenergic stimulation and reduced cardiac reserve as would be expected if uncoupled 15, 35 (reviewed by Messer 17 ). The physiological manifestations of the uncoupling seen in unloaded filaments require further investigation.
Clinical relevance of re-coupling by EGCG
Ca 2+ antagonists have been suggested as being potentially useful for treatment of HCM. 52 EGCG represents a new class of Ca 2+ antagonists with a very favourable functional profile. EGCG acts directly on the Ca 2+ regulatory system of the thin filament that is also the main target of HCM-causing mutations in sarcomeric proteins. 5 By binding to troponin, it decreases the enhanced Ca 2+ sensitivity characteristic of HCM while also reversing the uncoupling effect we observed in HCM mutations. The ability to restore coupling to DCM mutant myofibrils could be beneficial, since this was proposed to be the primary cause of DCM, but the reduction in Ca 2+ sensitivity in cases where the mutation also reduces Ca 2+ sensitivity may be deleterious.
EGCG has a wide range of pharmacological properties; indeed, it has been cited as an example of a promiscuous molecule. 53 Moreover, low doses of EGCG have a positive inotropic effect in intact heart muscle, due to effects on the ryanodine receptor type 2, Na + -K + ATPase and Na + -Ca 2+ exchanger, that may override the Ca 2+ -desensitizing effect in the contractile apparatus. 54, 55 Although EGCG is too non-specific to be a viable drug for treating HCM, this study has demonstrated a significant proof of principle: it is possible to directly reverse the molecular mechanism of HCM-causing mutations pharmacologically. The coupling of Ca 2+ sensitivity to cTnI phosphorylation has been demonstrated to be a labile property of troponin. HCM or DCM mutations and Ca 2+ sensitizers can induce uncoupling, indicating that small perturbations can destabilize troponin. 9, 17, 32 It is very unusual to find a reagent that will give a gain of function by apparently restoring the native conformational state in the presence of mutations that destabilized this state. Our findings provide a starting point for investigating molecules related to EGCG that may be more efficacious and act specifically on troponin. 56 
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Supplementary material is available at Cardiovascular Research online.
